Can a stronger zap to brain tumors be safer? new trial aims to find out

NCT ID NCT02390518

First seen May 23, 2026 · Last updated Jun 23, 2026 · Updated 8 times

Summary

This early-stage trial tests whether giving a higher dose of focused radiation (stereotactic radiosurgery) to brain metastases is safe. About 50 people with 1 to 5 brain tumors who have never had brain radiation will receive an experimental dose on one tumor, while other tumors get standard doses. The goal is to find the highest dose that does not cause severe side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Huntsman Cancer Institute

    RECRUITING

    Salt Lake City, Utah, 84112, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

stereotactic radiosurgery (high-dose radiation)

What this could lead to

If successful, this could establish a safer, more effective radiation dose for treating brain metastases that have not been previously irradiated.

What could go wrong

This is an early Phase I trial with only 50 participants, so results may not apply broadly. Higher radiation doses also carry increased risk of brain toxicity.

Conditions

The condition(s) this trial relates to.

brain cancer metastatic malignant neoplasm in the brain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.